Artivion vs CONMED
CONMED reported revenue of $1.4 billion in fiscal 2025, 3.1 times Artivion's $441 million in fiscal 2025. Artivion's revenue grew 13.6% in its latest year, and CONMED's grew 5.2%. Artivion had an operating margin of 7.7%, against 7.5% at CONMED. Free cash flow was $1 million at Artivion and $151 million at CONMED.
Side by side
| Artivion | CONMED | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $441M | $1.4B |
| Revenue growth | 13.6% | 5.2% |
| Revenue growth a year, last 5 years | 11.8% | 9.8% |
| Gross margin | 64.4% | 54.6% |
| Operating margin | 7.7% | 7.5% |
| Net margin | 2.2% | 3.4% |
| Free cash flow | $1M | $151M |
| Free cash flow margin | 0.2% | 11.0% |
| Return on capital | 3.9% | 3.7% |
| Net debt to EBITDA | 2.7x | 5.1x |
| Dividends and buybacks | $0M | $25M |
| Change in diluted share count | 13.2% | −0.0% |
| Last close | $22.98 | $47.68 |
| P/E at the last close | — | 31.6× |
| Insider trades, last 12 months | sold $20.4 million | sold $161,091 |
| Piotroski F-score | 7 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ArtivionCONMED
Operating margin
Percent of revenue
ArtivionCONMED
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArtivionCONMED